Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East

Figure 2

DAS28 to week 24. (a) Mean score over time. (b) Proportions of patients achieving DAS28 low disease activity (LDA; ≤3.2), DAS28 remission (<2.6), and clinically meaningful changes from baseline over time (change ≥1.2 from baseline). NA, not applicable. (a) for all visits after baseline versus baseline, based on Wilcoxon signed rank test. = number of patients with treatment administered at that visit. Follow-up visit for all patients. (b) = number of patients with treatment administered at that visit. Follow-up visit for all patients.

(a)

(b)